<SEC-DOCUMENT>0001628280-24-046827.txt : 20241112
<SEC-HEADER>0001628280-24-046827.hdr.sgml : 20241112
<ACCEPTANCE-DATETIME>20241112065549
ACCESSION NUMBER:		0001628280-24-046827
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20241106
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20241112
DATE AS OF CHANGE:		20241112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		241443142

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20241106.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0e618f5-ef39-46a9-8961-c3320445b2d1,g:b603df3f-612d-42b1-a578-4c0c74e2d253,d:258cfb00a78b44de99bb59a0edb4978f-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20241106</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20241106.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-06</xbrli:startDate><xbrli:endDate>2024-11-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i258cfb00a78b44de99bb59a0edb4978f_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">November 11, 2024 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 6, 2024</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i258cfb00a78b44de99bb59a0edb4978f_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2024, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221; or the &#8220;Company&#8221;) announced the U. S. Food and Drug Administration ("FDA") granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy ("DMD"). Cumberland is completing the FIGHT DMD&#8482; trial, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dmd-orphandrugrarediseased.htm">Exhibit 99.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:22.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmd-orphandrugrarediseased.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmd-orphandrugrarediseased.htm">Press release dated November </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmd-orphandrugrarediseased.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmd-orphandrugrarediseased.htm">, 2024</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="i258cfb00a78b44de99bb59a0edb4978f_7"></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 11, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dmd-orphandrugrarediseased.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8f05d62b97f2456dbabef506722d55c9_53"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:94px;margin-bottom:5pt;vertical-align:text-bottom;width:414px"></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">CUMBERLAND PHARMACEUTICALS RECEIVES FDA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">NASHVILLE, Tenn. (November 6, 2024) - Cumberland Pharmaceuticals Inc. (NASDAQ&#58; CPIX)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Cumberland is completing the </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">FIGHT DMD&#8482; trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">, a multicenter, double-blind, placebo-controlled Phase II study investigating the pharmacokinetics, safety and efficacy of once daily oral Ifetroban in patients with DMD. Results will be announced later this year.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#8220;For Duchenne muscular dystrophy, a devastating genetic disorder affecting young boys, securing both Orphan Drug and Rare Pediatric Disease Designations for Ifetroban from the FDA is a critical step forward,&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. &#8220;These designations not only recognize the urgent need for effective treatments but also provide vital support to accelerate research and development.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">These important regulatory milestones represent hope for families and a pathway to bring transformative medicines to a vulnerable patient population more quickly and efficiently.&#8221; </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The U.S. FDA grants Rare Pediatric Disease Designation to incentivize drug development for life-threatening diseases affecting less than 200,000 children in the U.S. As these diseases pose unique challenges to drug development, special focus is needed to provide therapeutic options to these children. Companies that receive approval for a drug or biologic with this designation may be eligible for a voucher which may be redeemed for priority review of a different product. Additionally, this voucher may be transferred or sold to another sponsor.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Orphan Drug Designation is granted by the U.S. FDA to encourage development of new therapies for rare diseases or conditions affecting fewer than 200,000 people in the U.S. This designation offers sponsors multiple incentives, which include exemption from user fees, tax credits for qualified clinical trials and potential market exclusivity for seven years following approval of the product. </font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">About Duchenne Muscular Dystrophy</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">DMD is a rare and fatal genetic disorder which affects about 1 in every 3,300 male births worldwide. Characterized by mutations in the gene responsible for producing dystrophin, DMD causes damage to the skeletal and cardiac muscle of DMD patients, with cardiomyopathy recognized as the primary cause of death. Ifetroban is being evaluated to treat the heart disease associated with DMD</font><font style="color:#b5082e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> which has received limited attention with current therapies.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">About Ifetroban </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Ifetroban is a potent and selective thromboxane-prostanoid receptor (TPr) antagonist. Ifetroban exhibits high affinity for TPr on many cell types including cardiomyocytes, platelets, vascular and airway smooth muscle, and fibroblasts, and lacks agonistic activity. In several preclinical models of muscular dystrophy</font><font style="color:#b5082e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> including limb-girdle and Duchenne, ifetroban prevented cardiac fibrosis</font><font style="color:#b5082e;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">and cardiac dysfunction and improved mortality.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland previously announced the acquisition of the ifetroban program in collaboration with Vanderbilt University and Cumberland Emerging Technologies. </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland is also evaluating ifetroban for systemic sclerosis and pulmonary fibrosis. The ongoing </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">FIGHTING FIBROSIS Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> is a multicenter, randomized placebo-controlled Phase II study in patients with idiopathic pulmonary fibrosis (IPF), a progressive interstitial lung disease. IPF is marked by inflammation and fibrosis of the lungs, resulting in rapidly declining lung function and reduced survival within five years of diagnosis. The study is evaluating the safety and efficacy of once daily oral Ifetroban for 52 weeks. </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:151%;text-decoration:underline">About Cumberland Pharmaceuticals</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. The Company develops, acquires, and commercializes brands for the hospital acute care, gastroenterology and rheumatology market segments. The Company's portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:20.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of pain and fever&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:20pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) for Oral Solution, a prescription laxative, for the treatment of chronic and acute constipation&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:12pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:700;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">granisetron</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) Transdermal delivery system, for the treatment of nausea and vomiting associated with chemotherapy.</font></div><div style="margin-bottom:6pt;padding-right:12.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company&#8217;s website </font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">www.cumberlandpharma.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">About Cumberland Emerging Technologies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland Emerging Technologies, Inc. (</font><font style="color:#0563c1;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;text-decoration:underline">www.cet-fund.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University, Launch Tennessee and WinHealth Pharma. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET&#8217;s Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.&#160;</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:133%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:133%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure, natural disasters, public health epidemics, and other events beyond our control, as more fully discussed in the Company&#8217;s most recent Form 10-K and subsequent 10-Qs as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:133%"><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Investor Contact&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media Contact&#58;</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Shayla Simpson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Molly Aggas</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Cumberland Pharmaceuticals&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dalton Agency</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">(615) 255-0068&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(704) 641-6641</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20241106.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0e618f5-ef39-46a9-8961-c3320445b2d1,g:b603df3f-612d-42b1-a578-4c0c74e2d253-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20241106" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20241106">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20241106_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20241106_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20241106_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0e618f5-ef39-46a9-8961-c3320445b2d1,g:b603df3f-612d-42b1-a578-4c0c74e2d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e4f2c9d1-823b-4d50-938f-d487afddd224_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0ca6262f-402e-40b4-8699-e98e89f8a28b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_635f2024-dd80-4141-99de-381845b0fd89_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fd50f83e-29cb-430f-aa91-9c412d7f7703_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_09bd54f9-1785-4830-934d-6f66e0cd193d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9b7ab9a1-aac2-4dc9-bcb6-f94c081f33d1_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_299d64e3-61e9-4bd7-b202-41b9214f9fe1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bc82e66a-d47e-4804-b4ce-f58980614e7f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9d559970-4b3f-436d-b9db-7da37eb0c9d1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_b97d0ec4-f2c9-4efe-b284-79cce23b433c_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_8dbd53cf-2a89-42f2-8350-c12778da8b85_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_6e609ef5-7ae4-443a-96da-4e973f28c0da_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_69d72604-ca53-4e10-afcd-a6ef9f9dc8bb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_fdea5af7-fdd6-4db0-bec9-1d2025f411e7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7356818f-c4c5-4c67-87db-ebb84a612e52_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a207fe14-7803-4f77-b936-b3b38b41528f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3bd2295a-78d4-4819-ad22-5b5786157887_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_3316e531-bc97-4ef5-a78d-ed165bcd1211_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1715f743-2570-41b8-a29d-803482716738_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f36c6bad-7fef-45ff-a05f-2a06fa9725c7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_1e8182e5-28a6-4ec7-8b33-31fd7f6d5aa5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2cef64a-4680-47e8-83ae-0e642754ae63_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_40f1d68d-94fb-4a68-9c73-ff86ca38d63f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20241106_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:b0e618f5-ef39-46a9-8961-c3320445b2d1,g:b603df3f-612d-42b1-a578-4c0c74e2d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20241106.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c3cc0f39-feb1-4dc3-afa0-0fe7ab2e2d49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_DocumentType_c3cc0f39-feb1-4dc3-afa0-0fe7ab2e2d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fddcd799-77da-400a-ac9e-cdaee6f6de66" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_DocumentPeriodEndDate_fddcd799-77da-400a-ac9e-cdaee6f6de66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_870060db-7815-4e78-809b-20256bb07b60" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityRegistrantName_870060db-7815-4e78-809b-20256bb07b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ab7333a3-2a04-4bbf-bf98-b2f5d80f5270" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityCentralIndexKey_ab7333a3-2a04-4bbf-bf98-b2f5d80f5270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_afe2b97c-4de8-4ec2-a3c7-721f28fa2132" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_AmendmentFlag_afe2b97c-4de8-4ec2-a3c7-721f28fa2132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f237c728-4310-4e1d-87fd-991c6aae5b9a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f237c728-4310-4e1d-87fd-991c6aae5b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3c80febf-870f-4dbf-915f-9ba1834c8f1e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityFileNumber_3c80febf-870f-4dbf-915f-9ba1834c8f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f93901f8-7013-4a9f-bd3b-1b1f2d0192d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityTaxIdentificationNumber_f93901f8-7013-4a9f-bd3b-1b1f2d0192d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_4195231f-1266-4c88-8531-3d44a5b8c9a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_CityAreaCode_4195231f-1266-4c88-8531-3d44a5b8c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b27786e9-dc56-4463-b968-3029f612fdbb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_LocalPhoneNumber_b27786e9-dc56-4463-b968-3029f612fdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_9f577829-fb1a-4e98-94af-7145778533ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_WrittenCommunications_9f577829-fb1a-4e98-94af-7145778533ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_af4d66bf-430b-4da8-ad7a-d546aeb8d876" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_SolicitingMaterial_af4d66bf-430b-4da8-ad7a-d546aeb8d876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_be1fd931-cf5e-45f3-9ef8-8ef7415927bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_PreCommencementTenderOffer_be1fd931-cf5e-45f3-9ef8-8ef7415927bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_ca32a763-3e09-48f9-8663-5adda383c1b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_ca32a763-3e09-48f9-8663-5adda383c1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_02cbf878-e1d1-4ba5-8787-b4bad521bd48" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_Security12bTitle_02cbf878-e1d1-4ba5-8787-b4bad521bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e13ce25-0110-4493-8133-199017734311" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_TradingSymbol_2e13ce25-0110-4493-8133-199017734311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b5c78510-3cba-4b1b-ad7e-f6425e9f1d65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_SecurityExchangeName_b5c78510-3cba-4b1b-ad7e-f6425e9f1d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_75cc1b13-6a31-409b-b236-164fc3d59d20" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityEmergingGrowthCompany_75cc1b13-6a31-409b-b236-164fc3d59d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6fb9be8a-72ea-48eb-96c0-8dec8f796156" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityAddressAddressLine1_6fb9be8a-72ea-48eb-96c0-8dec8f796156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_051c687e-b47b-4566-b51a-8ad25a50161d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityAddressPostalZipCode_051c687e-b47b-4566-b51a-8ad25a50161d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_77613f79-c333-4f37-83cf-7d0321cdb740" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityAddressCityOrTown_77613f79-c333-4f37-83cf-7d0321cdb740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_294c89e7-cfaa-4fcf-a318-fc984de07783" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_d41683cb-079b-4d62-92f6-95ad0505ab84" xlink:to="loc_dei_EntityAddressStateOrProvince_294c89e7-cfaa-4fcf-a318-fc984de07783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !> 9X# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\\^*7Q2\#_!OP3K7Q ^(6N6V@>&M$A1[
MF[G^>:YN)Y%AL],TZU7,^H:KJ-P\=M8:?;(]Q=3R*D:XW,OH1. 3Z G\J_E
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MZ1]UIMM]>5:;]_WDZT5_'U9?\%!OVQ?!TR2Z7\<O$]ZD(.+?Q';:)XH@D (
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MV<Y1E1UK4JU.=&K325VY0FD[:/5)JZ9]045^-_P+_P""B_Q4\7?&*\\#>/\
MPAX-U;PWI7Q67X,>.KSP)I$VDW'PO\;:K\4?%GP<\*[]8E^*/Q!E\<Z/KOQ
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M#>>'UB?7;31=2NM'CGA,\$VI6UG--9PS0AXC)%-<1QQ2*LL;E';9)&P5QD>
M_'_A[XA:+#J^A7<;N$B&HZ:TB&_TFZD3>;6]A&&4G#&WN%!MKV +=6DLT#K(
M<5BL1'#3PD*DH8>I5C6JTXMI5:E./+3=2WQJE&53V:E=0=2;6LFRW3@YJHTG
M.,7%-_93:;2[<S2N]]%8[>BBBL"PK\P_^"J?@+QQ\0?@GX"TOP'X.\4>-=2L
MOBE::C>:=X4T'5/$%]:V">$?%ELU[<6FDVMW/#:+<7,$#7$D:Q+-/#&7#R(K
M?IY1@9SWH _B4\4_LZ_M 6$<LM[\#OB]:1*KLSW'PX\80JH +;B9-'4  <D]
MAGTKY(\;^&_$7A^22/7M UO0Y X7R]7TF_TR3>#G;LO;>!MP[KC(':O]"*LW
M5-&TC6[9K/6M*T[5[-PRO:ZG8VU_;.K JP:"ZBEB8,I*L"A!4D'()% '\.'[
M-VK:IH.H:-K&BZC?:1JVFSQ7>GZGIEU/97UE<QL/+GMKNV>.:"1<G#QNIP2,
MX8@_U5_LB_M37OQ,TRP\&_$:>#_A,XX%32M?2.*U@\41PQ%G@NH8@D%MKR1(
M92($BM=2C262&*WN4,,WI'C/]B#]EKQJ9+BY^#OA/P[JKDNFL^![,>"=1CF(
M91/(/#GV"QU!U#DB/5K+4+=F"-) Y1"OSUJG[&NN?"NY77/ASK=_XFT:PFBO
M(["=8[?QAHYM9!/#=V%Q9I':ZU/:21I<QFUM]-U&.2)!9V=_<E10!^F=?S\_
M\',8S_P2\\3GT^-/P@_].NI?Y_0\5^YGPV\5GQIX,T;79BGVZ6!K74UC4(@U
M*R=K:[>.,9\N"Y>,7EM&3N6UN8=X5L@?B)_P<J:1J>J?\$M?'UQI]G/=P:#\
M5?@_K6KR0(SBQTL^*/['^V3A5;; -1U?3K9I#@*]U'D@$D?3\%R4.+>')2:B
MEG&!NV[+6O!)7?=NWS/.S:[RS'V5W]4K=+_8?3J?9/\ P1S_ .47_P"Q/_V0
M_0/_ $KU&OT9UK1M,\1:/JV@:S:I?:1KFFWVCZK9.\D:7FFZG:RV=]:N\+QS
M(EQ;32Q,T4B2*&W(ZN%8?S.?\$T_^"T?_!-KX"?L&_LN?!SXK_M&6_A7XC?#
MSX5Z/X<\7^'6^'/Q8U5M)UBUN+V2>S.HZ+X'U#2KLQK*A,UC>W,#;L)*V#CZ
MX\>?\%_O^"7C>!O&8\&?M66X\8'PKXA'A0I\*/C 6'B7^R+O^PL#4?AP=/W?
MVI]E(%\&LCC_ $H&#S!79G'#/$=;/<TG1R+.'"MF^.G2K0R[&>SE&>,J2A5C
M4A1:]GRM34XW7*FU=6,L+F. A@\,I8S#)QPU%2A*O24DU2AS)Q<TU);-/6^F
MY^D'[,7[&?[,_P"QIH'B?PQ^S/\ "O2?A7H/C+5[37_$NG:3JOB/58M5U>QL
MAI]K>RR>(]9UF>)XK,"$);RPQ$?,T;/\U?RT_P#!R1_R?U_P30_Z[6?_ *N;
MP?7Z2?\ !O+^V1^UA^VO\ ?CO\1OVJ/B/=_$V_\ #GQ<TSP?X)UNX\&^!?!T
M5II]OX.TO5]:TZW@\!^%/"NG:@8[O5K*>6XO(+RZA:981-'&1&?S5_X.;9AX
M1_;"_P""<?Q(\017&G^"='_M:;4/$!M;F>SA'A3XG^!=>U^,"VBFEFN-/TB^
MM+V2UMXY;EXIH_*B=G53]'PK@<?EWB+5R[,L4L=F-'#9C1K8B-:MB/;UGE%6
M<8QJ5HQK5)1@XT[2@I<T>1*T4>?F=6AB,BC7PU/V-"4\-.,'&%-0A];IW;C!
MN$(W3=[VL[[,_LZK\KO^"W _XU6?MF^WPTTT_P#E\>$Z\]_X?_\ _!)C S^U
M9:YQR!\*?C7P>_/_  KKG\,U\ ?\%3/^"R__  3A_:)_8 _::^"WP?\ VB+?
MQ=\2?B!X&LM(\)>'%^'?Q5TAM5U&'Q5X>U*2!=2USP/INDVA%G97,HDO;^VB
M/E% _F,BM\YD'#7$5#/<DJ5LASFE3I9MELZM2IEF-A3IPIXRA*<ZDY48J$(Q
M3E*4FHQBFY-)'H8W,,!+!XM1QF%E*6&Q$8Q6(I-RDZ4DHI*3;;;222U;T/KC
M_@V^_P"44GP;_P"Q^^-?_JS?$%? W_!<CPKX?\=_\%9O^"0'@?Q9IEKK?A7Q
MGXX\->$O$^BWJ>99ZQX>\1_'#P;H^M:5=QY7S+74=-O;FSN8\_/#,Z=&Q7Z&
M?\&Z&C:EI'_!*'X$OJ-I-:C5_%7QCUG3_.0H;G3;GXI>*((+N,$ F&:2UG\M
M\8=5W*2I!/PG_P %FO\ E,E_P18_[*W\/S^7[0?@,U]'ELG'Q)XCG"7O0EQC
M*$XNS4H8',K2BUJFFKIK5=#S\0K\/X!-:/\ LI--;IU\/NNS7X'F?[('C/QC
M_P $,O\ @H?KG[!OQJUW4+K]AK]JGQ ?%/[.7Q+UZ=GT[P?XDU:XATS2O[3U
M!MMI9S/=?8O /Q)A*0K%J,'@[QT\>FZ'J-T]U])?\%M?VD_B7^TA\3_A=_P1
MX_9#O_MOQ:^/][I&I_M">(=/EF:R^'OPI^75XM%\075GE[&RU#3+>7QGXR4R
M1W \(:;I6DQ0WH\:);5^IO\ P5$_X)]>#/\ @HI^R[XD^$>I+8:1\3/#XG\7
M?!/QU<QD2^$OB%96CK:17-S$KW \->)X-V@>*;5$F#:?=1ZG!;R:II&ERP?'
M7_!$_P#X)B_$#]CSPGXZ_:$_:PEG\3?MH_'&X?3_ !=J^N>)+?QQK'@;P%HM
MU';:/X4C\76]_JUMJFH>(&TRQU[Q%>V.I7-O):VGA?1 X_L"3?S4\ZR/$4Z7
M&&,G"7$^7TEAIY9*"]GF>;Q4(Y?GDTO<]E1I*57&PY;5,9AJ*T=;W])83&PD
M\KI*2RZM-U(XE-J>&PRDG6PB=OCE*T:,FVU2G-:\D>7\:OV9_P!F[P%^R)_P
M<@_!K]G+X:1W \(?"WX+:9H5G>7NS^T-:U*?]D6[U3Q%XCU/R_W8U+Q)XBU#
M5==OTAQ;176H20VJ1VL<,:?UQ_MH_P#)G7[6'_9M/QUQ]?\ A5_BG'X9Z^U?
MS0:I_P K8^G>_P /+(^O_-GK_P!*_I?_ &TO^3.OVL/^S:OCK_ZJ_P 4UAQC
M7K8K,."<17J2JXBOPUP]6KU9N\ZE6KB:TYSF]+RFVVW:UWY6*RJ,:>'S>$$H
MPIYAC80BM(QC&$%&*MT44DGV5[6T7\,'_!'#_@J=\;OV%O@#\1OAK\,/V%OB
M9^U)HWBGXM7GC:^\9^"K[Q?:Z=H.I7'@_P )Z(_AJZ3P_P#"_P <6S7D5MHM
MOJ;-/J-I.8-2A#60C"33?KI+_P '%'[7"QN__#G[X]1@(Q+MK'Q,V* IRS'_
M (9[.%'\1)X&:^2O^#>G_@I7^Q-^Q=^RM\7OA]^TM\;+#X9>,/$WQZU#QAHF
MCW7A/QYX@DOO#D_P_P# NC1:BMUX5\+:Y90HVI:1J-MY%Q<Q7(-L9&A$4D<C
M_OB__!?#_@DVJ,P_:ST=B%)VK\-?C&6;'.T#_A7I)8\@#!YXQFOJN*J-.?$>
M:M^&N,S?FQ3_ .%&G7X@A3QEH4_WW+A4\/%-735*\59Z-W1YN63DL!A+9_3P
MJ]FKX=QP;E2L[\EZOOW3LVY/?575D?C?_P &Y^BM\>?VT/VZOVZ?$7C#P+X?
M\;_$&Z\86&J? #2=1U6;QQX,E^)GQ-M_'>IZKKMCJ^D::R^'+"YT*VT#1M2L
M;B_:]OFU&+5(M(N[2.TF_1'_ (.8_P#E%UXI_P"RT_![_P!.^HU^2G_!"OQQ
M8_'#_@MK^WE\=/A9;ZS+\&_'7A;X^^*]/U%K&ZTJQ_LSQS\>? NM^!1J]A(J
M"RU#4].M]4O+"QO(UO84@U >7&\-RH_6O_@YC_Y1=>*?^RT_![_T[ZC7'FE.
M=/Q3X<YVX<]7AN4,(TN; 4W3H*.!GIS2G0L[RJ)3FI)R3>IT81I\-X]JSM#'
M1=5:QKM2;]LO*HY7LFXW^%L_)3]A?_@NI\=/V<OV1_@+\#O#G_!-KXQ_%G0_
MAKX#L?#6F?$?0M;\7V^C^+K:WNKR9=7T^"P^#NNVD=O*T[QJL&KZ@F8VQ<,>
M%_HX_P""9G[?OC_]OOP5\3_%GC[]F'QM^S#=_#_Q3HWAW3]!\:WVM7]UXHM]
M4TF74YM6LGUGP5X+DCM[*1%LY%@MKU#(P+3QMB,_F3_P3*_X+)_\$W?@-^P1
M^RY\'OBQ^TGI?A/XC?#_ .%^FZ!XN\-S> _BCJ4NCZO;WU_-+:/?:/X)U#2[
MIDCFB;S;*]N86W860L& ^ZO^']__  2:Z_\ #6NC_P#AMOC(/T_X5[^OX5YG
M%&75<;BLUH8'P\S3#XN>8XB<,WI2SS%>U4<4Y3K0P]2E+#.&*C=I0]R*FITG
M:*OMEM>-.GAIUL\PU2FJ$%+"R6$I<C]G!*+J*2G^[^%/=VL[ZL_82OX%O /[
M9WP6_81_X. _VX?CG\>;CQ-;> SXK^.W@WS/">@MXCU;^VO$&O>&;C3E_LY;
MJS/V8II5V9Y_._=$1@H=X(_MX_9V_:1^"_[5_P +]*^,_P  ?&L'Q ^&NMZA
MK&EZ9XEMM*UW18KF_P! U";2]6MQ8>(],TC5(S:7T$L!>6Q2.0H7A>2,AC_(
M-^Q?\.OA_P#%#_@Y*_;B\,?$OP-X0^(7AO[7^T7J7_"/^-_#>C^*M%_M"T\1
M>#%M+[^R]<L[ZQ^UVRSS+!<^1YT2RR"-U$C \O M.EA5QG3S3#8I4:'#.,AC
M<+"2PN+2AB\*JM%2JTYJA633B^>E+EDG>-T:YQ*55Y1+#5*?-/'TW2J->TIW
M=.?+*T6N:/H]=[L_5C_B)L_X)A]M7^.G_AI)OR_Y#_X?_6K\:_V;?VC?"?\
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MK+Q,ZZ?K&A6.DZOH4I\1?$GQ)8>)/%]AK4-_!<V?A;PSH%O<>9)86('W>/\
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ML[N%)89K>>*08:,L8I)$>U\&?@I\+OV>_AWH?PF^#7@_3O 7PY\,G4/^$?\
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MOV7=4\"W_P *+&R^&_PX^+7PM\(Z#K.M:3I_A7XT^&?'WA?QFDTMPFM7U_\
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45892318503904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  06,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M7>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " #W-FQ9)!Z;HJT
M  #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O
M$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S
M)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^
M0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@
MXLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ ]S9L6660
M>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;
M)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=
M]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T
M<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JK
MA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#
M(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[
M04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%0
M2P$"% ,4    " #W-FQ9!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /<V;%D2[B]Y[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M /<V;%F97)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ ]S9L60V$1.=E!   JQ   !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M /<V;%F?H!OPL0(  .(,   -              "  :D,  !X;"]S='EL97,N
M>&UL4$L! A0#%     @ ]S9L69>*NQS     $P(   L              ( !
MA0\  %]R96QS+RYR96QS4$L! A0#%     @ ]S9L61PX9>H_ 0  / (   \
M             ( !;A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( /<V
M;%DD'INBK0   /@!   :              "  =H1  !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( /<V;%EED'F2&0$  ,\#   3
M          "  ;\2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D
*/@(   D4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20241106.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20241106.htm">cpix-20241106.htm</File>
    <File>cpix-20241106.xsd</File>
    <File>cpix-20241106_lab.xml</File>
    <File>cpix-20241106_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20241106.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20241106",
   "dts": {
    "inline": {
     "local": [
      "cpix-20241106.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20241106.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20241106_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20241106_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20241106.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20241106.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-24-046827-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-046827-xbrl.zip
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M>VJ&6>,^P$<(".%)M(%.7W0TT-%'!E C5SKAR15J^Z!J"K840.R5/IZT2_N
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M0&/&@&944V8H1U2XX?Y$81K -Z)!K1I865>:G]9E*+\CW'H1.]RH!YX]9D8
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M\6*I.^)D4.TUU*1K_T#?S:1+?G^F;-34;"9-FS8?"X40B[C%31% *&2 VV=
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M_@([\YN;G-Y["ZK>QG+BO2VYR)#Z\&QV=(6,C$B:[.0DKS'B-5VE09(CQRT
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M-U!+ 0(4 Q0    ( /<V;%G4648O<@\  &=L   1              "  0
M  !C<&EX+3(P,C0Q,3 V+FAT;5!+ 0(4 Q0    ( /<V;%FG5 SS?0(  &8'
M   1              "  :$/  !C<&EX+3(P,C0Q,3 V+GAS9%!+ 0(4 Q0
M   ( /<V;%GM&&1>/0H  (Q5   5              "  4T2  !C<&EX+3(P
M,C0Q,3 V7VQA8BYX;6Q02P$"% ,4    " #W-FQ9D1$HLKX&  !#,0  %0
M            @ &]'   8W!I>"TR,#(T,3$P-E]P<F4N>&UL4$L! A0#%
M  @ ]S9L6>;B*3-:$0  I5<  !X              ( !KB,  &1M9"UO<G!H
L86YD<G5G<F%R961I<V5A<V5D+FAT;5!+!08     !0 % % !  !$-0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cpix-20241106_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20241106.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2024-11-06</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-11-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
